AUC versus peak-trough dosing of vancomycin: Applying new pharmacokinetic paradigms to an old drug

Therapeutic Drug Monitoring

Volumn 35, Issue 4, 2013, Pages 443-449

  Brown, Daniel L ^a   Lalla, Christina D ^a   Masselink, Andrew J ^a  

^a PALM BEACH ATLANTIC UNIVERSITY   (United States)

Author keywords

AUC; dosing nomogram; therapeutic drug monitoring; vancomycin

Indexed keywords

VANCOMYCIN;

AREA UNDER THE CURVE; BACTEREMIA; BODY WEIGHT; COMPARATIVE STUDY; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG MONITORING; DRUG TREATMENT FAILURE; ENDOCARDITIS; HUMAN; KIDNEY FUNCTION; LOADING DRUG DOSE; MENINGITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NOMOGRAM; OSTEOMYELITIS; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; DRUG DOSAGE CALCULATIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; VANCOMYCIN;

EID: 84880569726     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31828b2a50     Document Type: Review

References (33)

1. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66:82-98.
2. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator- associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388-416.
3. Grace E. Altered vancomycin pharmacokinetics in obese and morbidly obese patients: what we have learned over the past 30 years. J Antimicrob Chemother. 2012;67:1305-1310.
4. DeRyke CA, Alexander DP. Optimizing vancomycin dosing through pharmacodynamic assessment targeting area under the concentrationtime curve/minimum inhibitory concentration. Hosp Pharm. 2009;44: 751-765.
5. Blouin RA, Bauer LA, Miller DD, et al. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother. 1982;21:575-580.
6. Marsot A, Boulamery A, Bruguerolle B, et al. Vancomycin: a review of population pharmacokinetics. Clin Pharmacokinet. 2012;51:1-13.
7. Matzke GR, McGory RW, Halstenson CE, et al. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother. 1984;25:433-437.
8. Ducharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. Ther Drug Monit. 1994;16:513-518.
9. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006;42:S35-S39.
10. Murphy JE, Gillespie DE, Bateman CV. Predictability of vancomycin trough concentrations using seven approaches for estimating pharmacokinetic parameters. Am J Health Syst Pharm. 2006;63:2365-2370.
11. Moellering RC, Krogstad DJ, Greenblatt DJ. Vancomycin therapy in patients with impaired renal function a nomogram for dosage. Ann Intern Med. 1981;94:343-346.
12. Brown DL, Mauro LS. Vancomycin dosing chart for use in patients with renal impairment. Am J Kidney Dis. 1988;11:15-19.
13. Lake KD, Peterson CD. A simplified dosing method for initiating vancomycin therapy. Pharmacotherapy. 1985;5:340-344.
14. Kullar R, Leonard SN, Davis SL, et al. Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15- 20 mg/L suggested by the vancomycin consensus guidelines. Pharmacotherapy. 2011;31:441-448.
15. Patel P, Pai MP, Rodvold KA, et al. Vancomycin: we can't get there from here. Clin Infect Dis. 2011;52:969-974.
16. Moise PA, Schentag JJ. Pharmacokinetic and pharmacodynamics modeling of antibiotic therapy. Curr Opin Infect Dis. 1998;11:673-680.
17. Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillinresistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008; 46:193-200.
18. Lui C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillinresistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011;52:5-92.
19. Jeffres MN, Isakow W, Doherty JA, et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest. 2006;130:947-955.
20. Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections. Arch Intern Med. 2006;166:2138-2144.
21. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis. 2012;54:755-771.
22. Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother. 2008;52:3315-3320.
23. Lodise TP, Lomaestro B, Graves J, et al. Larger vancomycin doses ($4 grams/day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008;52:1330-1336.
24. Rodvold KA, Blum RA, Fischer JH, et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother. 1988;32:848-852.
25. Sanchez JL, Dominguez AR, Lane JR, et al. Population pharmacokinetics of vancomycin in adult and geriatric patients: comparison of eleven approaches. Int J Clin Pharmacol Ther. 2010;48:525-533.
26. Rybak MJ, Boike SC. Individualized adjustment of vancomycin dosage: comparison with two dosage nomograms. Drug Intell Clin Pharm. 1986;20:64-68.
27. Karam CM, McKinnon PS, Neuhauser MM, et al. Outcome assessment of minimizing vancomycin monitoring and dosing adjustments. Pharmacotherapy. 1999;19:257-266.
28. Kullar R, Davis SL, Taylor TN, et al. Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort. Pharmacotherapy. 2012;32:195-201.
29. Reynolds DC, Waite LH, Alexander DP, et al. Performance of a vancomycin dosage regimen developed for obese patients. Am J Health Syst Pharm. 2012;69:944-950.
30. Aubron C, Corallo CE, Nunn MO, et al. Evaluation of the accuracy of a pharmacokinetic dosing program in predicting serum vancomycin concentrations in critically ill patients. Ann Pharmacother. 2011;45: 1193-1198.
31. Wilhelm SM, Kale-Pradhan PB. Estimating creatinine clearance: a metaanalysis. Pharmacotherapy. 2011;31:658-664.
32. Winter MA, Guhr KN, Berg GM. Impact of various body weights and serum creatinine concentrations on the bias and accuracy of the Cockcroft- Gault equation. Pharmacotherapy. 2012;32:604-612.
33. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2009;29:1275-1279.